PubMed:32178765 / 875-1176 JSONTXT

Annnotations TAB JSON ListView MergeView

    Inflammaging

    {"project":"Inflammaging","denotations":[{"id":"T7","span":{"begin":0,"end":301},"obj":"Sentence"},{"id":"T7","span":{"begin":0,"end":301},"obj":"Sentence"}],"text":"Eligibility criteria included inadequate response to or intolerance of standard treatment, including at least 4 months of apremilast, at least 3 months of non-biologic disease-modifying antirheumatic drugs (DMARDs), or at least 4 weeks of non-steroidal anti-inflammatory drugs for psoriatic arthritis."}

    yaoziqian_800_3

    {"project":"yaoziqian_800_3","denotations":[{"id":"T7","span":{"begin":281,"end":300},"obj":"DP"}],"text":"Eligibility criteria included inadequate response to or intolerance of standard treatment, including at least 4 months of apremilast, at least 3 months of non-biologic disease-modifying antirheumatic drugs (DMARDs), or at least 4 weeks of non-steroidal anti-inflammatory drugs for psoriatic arthritis."}

    Zierdiyeerkenaili_800_3

    {"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T8","span":{"begin":281,"end":300},"obj":"DP"}],"text":"Eligibility criteria included inadequate response to or intolerance of standard treatment, including at least 4 months of apremilast, at least 3 months of non-biologic disease-modifying antirheumatic drugs (DMARDs), or at least 4 weeks of non-steroidal anti-inflammatory drugs for psoriatic arthritis."}